|
| Study | Country | Type of study | Audiological tests conducted | Patient population | Number of patients who developed ototoxicity |
|
| Nitz et al. [49] | Germany | Prospective longitudinal trinational population-based | Air (0.125–8 kHz) conduction pure tone audiometry | 93 patients with osteosarcoma and 19 with soft-tissue sarcoma receiving cisplatin and/or carboplatin containing chemotherapy | 55 (49.1%) |
|
| Knight et al. [55] | USA | Prospective | Otoscopy, tympanometry, pure tone audiometry (0.5–8 kHz), DPOAEs, and ABR | 32 children with different types of cancers treated with cisplatin and/or carboplatin containing chemotherapy | 20 (62.5%) |
| Otoscopy, tympanometry, extended pure tone audiometry (0.5–16 kHz), and DPOAEs | 17 children with different types of cancers treated with cisplatin and/or carboplatin containing chemotherapy | 16 (94.1%) |
|
| Coradini et al. [44] | Brazil | Retrospective | Tympanometry, pure tone audiometry (0.25–8 kHz), TEAOEs, and DPOAEs | 23 children with malignant hepatic tumour, osteosarcoma, and germ cell tumours receiving cisplatin containing chemotherapy | 12 (52%), pure tone; 5 (22%), TEOAEs; 16 (71%), DPOAEs |
|
| Bertolini et al. [56] | France | Prospective | Otoscopy, immittance audiometry, speech audiometry, play audiometry or free-field audiometry, conventional pure tone audiometry (frequencies not specified), or ABR (depending on the age of the participant) | 102 children with either neuroblastoma, hepatoblastoma, germ cell tumour, or osteosarcoma | — |
| 96 received cisplatin and/or carboplatin containing chemotherapy | 39 (41%) |
| 52 received cisplatin only | 19 (37%) |
|
| Stavroulaki et al. [57] | Greece | Prospective | Otoscopy, immittance audiometry, pure tone audiometry (0.25–8 kHz), TEOAEs, and DPOAEs | 12 children with either neuroblastoma, osteosarcoma, medulloblastoma, rhabdomyosarcoma, or primitive neuroectodermal tumour receiving cisplatin containing chemotherapy | 6 (50%) |
|
